Literature DB >> 12721945

Phagocytosis of Bordetella pertussis incubated with convalescent serum.

Paula S Mobberley-Schuman1, Beverly Connelly, Alison A Weiss.   

Abstract

Convalescent serum samples were examined for the ability to promote phagocytosis of Bordetella pertussis by human neutrophils. One sample promoted phagocytosis, and 11 of the 51 samples caused a statistically significant reduction in phagocytosis, compared with that of bacteria not incubated with serum. Phagocytosis was influenced by interactions between antibodies that promoted phagocytosis and antibodies that inhibited phagocytosis. Adenylate cyclase toxin (ACT) has been shown to block phagocytosis by neutrophils. Antibodies to ACT were removed from the sample that promoted phagocytosis, by incubation with ACT-coated paramagnetic beads, and the depleted serum no longer enhanced phagocytosis. The adhesin filamentous hemagglutinin (FHA) has been shown to mediate attachment of B. pertussis to neutrophils in a way that promotes phagocytosis. Depletion of antibodies to FHA from samples that blocked phagocytosis improved phagocytosis, compared with the no-antibody control. These results suggest that antibodies to ACT can promote phagocytosis, whereas antibodies to FHA can counteract beneficial opsonins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721945     DOI: 10.1086/374741

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Influence of CR3 (CD11b/CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils.

Authors:  Paula S Mobberley-Schuman; Alison A Weiss
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

2.  Characterization of serological responses to pertussis.

Authors:  Mineo Watanabe; Beverly Connelly; Alison A Weiss
Journal:  Clin Vaccine Immunol       Date:  2006-03

3.  Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway.

Authors:  Audun Aase; Tove Karin Herstad; Samuel Merino; Kari Torkildsen Brandsdal; Bjørn Peter Berdal; Erja M Aleksandersen; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2007-05-16

Review 4.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

5.  Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans.

Authors:  Ang Lin; Danijela Apostolovic; Maja Jahnmatz; Frank Liang; Sebastian Ols; Teghesti Tecleab; Chenyan Wu; Marianne van Hage; Ken Solovay; Keith Rubin; Camille Locht; Rigmor Thorstensson; Marcel Thalen; Karin Loré
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

6.  Interspecies variations in Bordetella catecholamine receptor gene regulation and function.

Authors:  Timothy J Brickman; Ryan J Suhadolc; Sandra K Armstrong
Journal:  Infect Immun       Date:  2015-09-14       Impact factor: 3.441

7.  Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model.

Authors:  Gordon Y C Cheung; Dorothy Xing; Sandra Prior; Michael J Corbel; Roger Parton; John G Coote
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

8.  Antibody-mediated neutralization of pertussis toxin-induced mitogenicity of human peripheral blood mononuclear cells.

Authors:  Scott H Millen; David I Bernstein; Beverly Connelly; Joel I Ward; Swei-Ju Chang; Alison A Weiss
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Role of Major Toxin Virulence Factors in Pertussis Infection and Disease Pathogenesis.

Authors:  Karen Scanlon; Ciaran Skerry; Nicholas Carbonetti
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

10.  Role of neutrophils in response to Bordetella pertussis infection in mice.

Authors:  Charlotte Andreasen; Nicholas H Carbonetti
Journal:  Infect Immun       Date:  2008-12-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.